Jones Trading cuts Aardvark Therapeutics stock price target on trial delay

Aardvark voluntarily paused its Phase 3 HERO and multiple Phase 2/3 trials for ARD-101/ARD-201 after cardiac safety signals (QRS prolongations), and the stock has plunged ~29% over the past week to $3.77 (52-week low $3.55). Analysts cut targets materially — Jones Trading to $19 from $33, B.Riley to $8 from $32, BofA to $21 while Raymond James kept a $28 Strong Buy and Cantor Fitzgerald stayed Overweight — and Jones Trading delayed Prader-Willi and obesity commercial launches by 1 and 2 years. The company reported $110M cash (runway into Q2 2027); the FDA has not issued a clinical hold and a formal FDA meeting is expected in Q2 2026, leaving regulatory outcome and possible lower-dose trial redesign as key near-term catalysts.

Analysis

The market is treating the situation as a binary regulatory event but the more likely path is a multi-stage derisking process that compresses peak sales more than it destroys them. A dose-dependent ECG abnormality creates a mechanical lever regulators and management can use: lower exposure, additional monitoring, or a new dose-optimization Ph3 rather than an outright program termination. That pathway tends to stretch timelines and increase capital needs rather than eliminate commercial opportunity, which favors balance-sheet resilient sponsors and well-capitalized competitors in the obesity/rare-hyperphagia space.

Second-order winners include large-cap obesity incumbents (who buy time to defend pricing) and vendors offering centralized ECG adjudication/remote monitoring, while small-cap peers with overlapping cardiac risk models will see correlation-driven deratings. CROs that can run additional thorough QT-like studies or in-silico cardiac modeling could capture incremental work as sponsors de-risk development programs. Conversely, mezzanine and secondary investors in similar-stage biotechs face amplification of funding squeezes: higher cost of capital and wider bid-ask spreads on follow-on financings.

Key catalysts and tail risks fall into timing buckets: near-term (days–weeks) volatility around any new safety readouts or FDA communications; medium-term (3–12 months) clarity from formal agency interaction and protocol amendments; long-term (12–36 months) readout or successful dose-reduction Ph3, or alternatively deeper dilution if a new trial is mandated. A positive reversal requires a credible mechanistic explanation (e.g., off-target ion-channel interaction amenable to dose or formulation change) plus demonstrable safety on adjusted exposure; absence of those specifics favors further downside.

Key Decisions for Investors

• AARD — Buy defined-risk downside protection: 3–6 month put spread 15–25% OTM sized to cover any existing long exposure (cost <3–5% of position notional). Rationale: protects against binary clinical/regulatory outcomes while keeping capital dry for a re-rating if safety is de-risked.
• AARD — Opportunistic asymmetric upside: buy 12–18 month call vertical (long-dated call spread) sized as a small percentage of hedge fund book (1–2% notional). Rationale: captures recovery if company successfully pivots to lower dose/new trial with capped premium loss; target 3x+ payoff if program re-enters pivotal path.
• Pair trade — Long LLY or NVO vs short AARD (equity or puts) over 3–12 months. Size long larger-cap obesity leader equal notional to short AARD to express rotation to high-confidence commercial franchises; expected payoff from market share reallocation and lower rehypothecation risk in large caps.
• Event-monitoring trade — Prepare to participate in any AARD financing only if post-money dilutive pricing implies >50–70% recoverable upside to current levels; otherwise, lean toward short-biotech basket exposure to capture widening cost-of-capital and sector de-rating over the next 6–18 months.